RCS - Immupharma PLC - Incanthera plc – Corporate Update & Board Changes

ImmuPharmaAnnouncement

04/06/2026 07:15

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260604:nRSD9924Ga&default-theme=true

RNS Number : 9924G  Immupharma PLC  04 June 2026

 

 

 

 

RNS REACH:
RELEASE
4 June 2026

ImmuPharma PLC

("ImmuPharma" or the "Company")

 

Incanthera plc - Corporate Update & Board Changes

 

ImmuPharma plc (LSE AIM: IMM), the specialist drug discovery and development
company, notes today's announcement by Incanthera plc, "Incanthera", regarding
a corporate update and subsequent Board changes. As part of the Board changes,
Tim McCarthy has stepped down as Executive Chairman of Incanthera: Link:
https://incanthera.com/ news-media/.

 

Ends

 ImmuPharma PLC (www.immupharma.co.uk.)
 Tim McCarthy, Chief Executive Officer and Chairman

 Lisa Baderoon, Head of Investor Relations           + 44 (0) 7721 413496

 SPARK Advisory Partners Limited (NOMAD)             +44 (0) 203 368 8974

 Neil Baldwin

 Stanford Capital Partners (Joint Broker)            +44 (0) 203 650 3650

 Patrick Claridge, Bob Pountney

 SI Capital (Joint Broker)                           +44 (0) 1483 413500

 Nick Emerson

 

Notes to Editors

 

About ImmuPharma PLC

ImmuPharma PLC (LSE AIM: IMM) is a specialty biopharmaceutical company that
discovers and develops peptide-based therapeutics. The Company's portfolio
includes novel peptide therapeutics for autoimmune diseases and
anti-infectives.

 

For additional information about ImmuPharma please visit www.immupharma.co.uk
(http://www.immupharma.co.uk/) .

 

ImmuPharma's LEI (Legal Entity Identifier) code: 213800VZKGHXC7VUS895.

 

About Reach announcements

Reach is an investor communication service aimed at assisting listed and
unlisted (including AIM quoted) companies to distribute media only /
non-regulatory news releases such as marketing messages, corporate and product
information into the public domain. An RNS Regulatory announcement is required
to be notified under the AIM Rules for Companies.

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRASSASILEMSEDM



            Copyright 2019 Regulatory News Service, all rights reserved